| Code: MTA6155 | Publication Date: Jul 2025 |
According to 6Wresearch internal database and industry insights, the herpes treatment market was valued at approximately USD 2.6 billion in 2025 and is projected to reach USD 3.8 billion by 2032, growing at a CAGR of 5.6% during the forecast period. This growth is fueled by increasing global herpes infection rates, growing awareness about STI treatments, and the rising availability of antiviral drugs.
The herpes treatment market is witnessing a notable transition driven by evolving patient needs and scientific advancements. There is a growing preference foronce-daily oral antivirals that offer improved adherence and convenience compared to traditional multi-dose regimens. Demand is also increasing fortopical treatments with enhanced skin absorption and longer-lasting symptom relief. Additionally,telemedicine platforms are significantly impacting how patients access diagnosis and treatment, especially in regions with stigma associated with STIs.
The herpes treatment market of herpes treatment is developing quite fast, as next-generation drug candidates are currently in clinical trials including long-acting injectables and therapeutic vaccines to it reduce the rate of recurrence. The CRISPR gene-editing technology, which is investigated in a potential elimination of latent herpes virus in nerve cells, is one of the most promising fields because it will cause a shift in the market, where symptom treatment is predominant, to the possible market of the cure. Nanoparticle-based systems are also being developed by biotech firms as antiviral drug delivery to allow better penetration and lower dosing frequency.